Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 5, 2012, Pages 278-283

  Chen, Chia Hao ^a   Yang, Jyh Chin ^b   Uang, Yow Shieng ^c   Lin, Chun Jung ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

antiplatelet activity; clopidogrel; prasugrel; proton pump inhibitors

Indexed keywords

CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; CONTROLLED STUDY; HUMAN; IC 50; LIVER MICROSOME; METABOLISM; THROMBOCYTE AGGREGATION;

DRUG INTERACTIONS; HUMANS; MICROSOMES, LIVER; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PROTON PUMP INHIBITORS; THIOPHENES; TICLOPIDINE;

EID: 84863720488     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1795     Document Type: Article

References (26)

1. Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O,. Upper gastrointestinal mucosal abnormalities and blood loss complicating low-dose aspirin and antithrombotic therapy. Aliment Pharmacol Ther 2006; 23: 489-495. (Pubitemid 43382003)
2. Ho PM, Maddox TM, Wang L, et al,. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
3. Ancrenaz V, Daali Y, Fontana P, et al,. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 2010; 11: 667-677.
4. Kreutz RP, Stanek EJ, Aubert R, et al,. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study. Pharmacotherapy 2010; 30: 787-796.
5. van Boxel OS, van Oijen MG, Hagenaars MP, Smout AJ, Siersema PD,. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010; 105: 2430-2436.
6. O'Donoghue ML, Braunwald E, Antman EM, et al,. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
7. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S,. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 2322-2329.
8. Small DS, Farid NA, Payne CD, et al,. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48: 475-484. (Pubitemid 351389118)
9. Pereillo JM, Maftouh M, Andrieu A, et al,. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 1288-1295. (Pubitemid 35265838)
10. Kazui M, Nishiya Y, Ishizuka T, et al,. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-99.
11. Rehmel JL, Eckstein JA, Farid NA, et al,. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006; 34: 600-607.
12. Li XQ, Andersson TB, Ahlström M, Weidolf L,. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-827. (Pubitemid 38955611)
13. Angiolillo DJ, Gibson CM, Cheng S, et al,. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011; 89: 65-74.
14. Harmsze AM, van Werkum JW, Taubert D, Hackeng CM, Deneer VH,. Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel's active metabolite. Ann Pharmacother 2011; 45: 542-543.
15. Hagihara K, Kazui M, Kurihara A, et al,. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009; 37: 2145-2152.
16. Tuffal G, Roy S, Lavisse M, et al,. An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost 2011; 105: 696-705.
17. Zahno A, Brecht K, Bodmer M, Bur D, Tsakiris DA, Krähenbühl S,. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. Br J Pharmacol 2010; 161: 393-404.
18. Born GV, Cross MJ,. The aggregation of blood platelets. J Physiol 1963; 168: 178-195.
19. Walsky RL, Obach RS,. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 647-660. (Pubitemid 38668158)
20. Yao M, Zhu M, Sinz MW, et al,. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. J Pharm Biomed Anal 2007; 44: 211-223. (Pubitemid 46551606)
21. Huang W, Lin YS, McConn DJ 2nd, et al,. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004; 32: 1434-1445. (Pubitemid 39564564)
22. Ohbuchi M, Noguchi K, Kawamura A, Usui T,. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica 2012; 42: 633-640.
23. Boulenc X, Djebli N, Shi J, et al,. Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite. Drug Metab Dispos 2012; 40: 187-197.
24. Ogilvie BW, Yerino P, Kazmi F, et al,. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos 2011; 39: 2020-2033.
25. US Food and Drug Administration. FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole. 2010. [27 Oct 2010].
26. Siriswangvat S, Sansanayudh N, Nathisuwan S, Panomvana D,. Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ J 2010; 74: 2187-2192.